Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

May 23rd 2024

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

May 21st 2024

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer

May 17th 2024

TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.

Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian Cancer

May 15th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.

Dr Asare on an AI Model to Predict PFS Outcomes in Ovarian Cancer

May 10th 2024

Amma Asare, MD, PhD on the use of AI for predicting PFS in ovarian cancer

Dr Chambers on FDA-Approved PARP Inhibitors in the Ovarian Cancer Treatment Arena

May 8th 2024

Laura J Chambers, DO, discusses currently approved PARP inhibitors that are considered for use in ovarian cancer.

Dr Cosgrove on the FDA Approval of Mirvetuximab Soravtansine for Frα+ Ovarian Cancer

May 8th 2024

Casey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.

Dr Mujumdar on Awareness Initiatives to Address Unmet Needs in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses how awareness initiatives can help address unmet needs in patients with ovarian cancer on World Ovarian Cancer Day.

TSP May Predict Chemoresistance and Survival Outcomes in Ovarian Cancer

May 8th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.

Awareness and Early Detection Remain Key Issues in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer

May 7th 2024

R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.

Dr Crane on the Ongoing Investigation of PARP Inhibitor Combinations in Ovarian Cancer

May 7th 2024

Phase 2 Trial Closure Clears a Path for Accelerated Development of Stenoparib in Ovarian Cancer

May 3rd 2024

A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.

Dr Garcia on the Future of the MELISA Trial in Ovarian Cancer

May 2nd 2024

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

Dr Hartwich on Preclinical Findings for Y3 Plus Chemotherapy in Ovarian Cancer

May 1st 2024

Yang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.

EVT801 Is Well Tolerated, Elicits Disease Control in Advanced Ovarian Cancer

May 1st 2024

Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.

Dr Konecny on PROs From the MIRASOL Trial in Advanced Ovarian Cancer

April 30th 2024

Gottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

April 29th 2024

Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.

Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer

April 29th 2024

Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

April 27th 2024

Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.